Global Green, Inc., gives Merial, Ltd., first option for license agreement

Global Green, Inc., announced on Wednesday that it signed an agreement with Merial, Ltd., to give Merial the first option to enter into a license agreement for the sale and distribution of its Salmogenic vaccine.

Merial, the Animal Health Division of Sanofi, will conduct an internal evaluation of the patented technology Global Green uses to develop its Salmogenic vaccine. Merial will have the first license option to distribute and sell the vaccine. The specific details of the evaluation are confidential.

Salmogenics is a patented salmonella vaccine that injects the drug into an egg before a chick is hatched to decrease the prevalence of salmonella in the chicken itself. The Salmogenic vaccine was developed to improve the health and well-being of approximately 40 billion broiler chickens and provide a healthier food source for humans in a more cost-effective way.

Salmogenics clinical trials have shown stronger immune systems, weight gain and decreased mortality in poultry that received the vaccine. The vaccine may decrease the need for antibiotics use with poultry, ultimately producing a healthier protein for human consumption.

"This agreement with a world leader in the animal health sector such as Merial further confirms the significance of our patented Salmogenics vaccine technology," CEO of Global Green Dr. Mehran Ghazvini said. "Our goal at Global Green, Inc., is to produce vaccines that improve early immunity in chickens and other animals providing a safer and more cost-effective food source. Global Green's approach to animal health is to produce innovative environmentally-safe products and solutions which enhance the health well-being and performance of animals."